OTCPK:SBHMY (Hong Kong)
Â
ADR
$
13.01
+0.53 (+4.21%)
10:08 PM EST
Business Description
Sino Biopharmaceutical Ltd
ISIN : US82937X1037
Share Class Description:
SBHMY: ADRTotal Employee Number:
21,435Compare
Compare
Traded in other countries / regions
01177.Hong KongSINOBIO19.ThailandSMZ1.GermanySBMFF.USA IPO Date
2014-04-22Description
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It has four main segments: oncology, liver, surgery/analgesics, and autoimmune/respiratory. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker for oncology after the Chinese government launched its volume-based procurement policy for the healthcare industry, whereby it reduces the price of its generic drugs in exchange for bulk procurement of its products. Oncology drugs make up its core innovative portfolio, while the other drugs are considered generic, which currently make up about half of its total revenue. Sino Biopharm competes with Hutchmed and Hengrui in the domestic oncology market, while it has a minimal presence in the global market.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.61 | |||||
Equity-to-Asset | 0.39 | |||||
Debt-to-Equity | 0.53 | |||||
Debt-to-EBITDA | 2 | |||||
Interest Coverage | 31.37 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 3.01 | |||||
Beneish M-Score | -2.87 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 8.4 | |||||
3-Year EBITDA Growth Rate | 9.5 | |||||
3-Year EPS without NRI Growth Rate | 19 | |||||
3-Year FCF Growth Rate | 20.1 | |||||
3-Year Book Growth Rate | 1.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 4.11 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 9.94 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 80.49 | |||||
9-Day RSI | 74.15 | |||||
14-Day RSI | 65.18 | |||||
3-1 Month Momentum % | -11.24 | |||||
6-1 Month Momentum % | -20.2 | |||||
12-1 Month Momentum % | -34.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.63 | |||||
Quick Ratio | 1.56 | |||||
Cash Ratio | 1.02 | |||||
Days Inventory | 128.09 | |||||
Days Sales Outstanding | 87.68 | |||||
Days Payable | 131.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.97 | |||||
Dividend Payout Ratio | 0.4 | |||||
3-Year Dividend Growth Rate | -2.1 | |||||
Forward Dividend Yield % | 2.35 | |||||
5-Year Yield-on-Cost % | 3.22 | |||||
3-Year Average Share Buyback Ratio | 1.1 | |||||
Shareholder Yield % | -2.98 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 82.44 | |||||
Operating Margin % | 30.14 | |||||
Net Margin % | 7.37 | |||||
EBITDA Margin % | 25.98 | |||||
FCF Margin % | 21.85 | |||||
OCF Margin % | 26.78 | |||||
ROE % | 7.83 | |||||
ROA % | 3.23 | |||||
ROIC % | 15.29 | |||||
3-Year ROIIC % | 9.04 | |||||
ROC (Joel Greenblatt) % | 87.81 | |||||
ROCE % | 16.95 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 37.5 | |||||
Forward PE Ratio | 17.82 | |||||
PE Ratio without NRI | 23.12 | |||||
Shiller PE Ratio | 20.19 | |||||
Price-to-Owner-Earnings | 18.81 | |||||
PS Ratio | 2.76 | |||||
PB Ratio | 2.77 | |||||
Price-to-Tangible-Book | 3.68 | |||||
Price-to-Free-Cash-Flow | 12.66 | |||||
Price-to-Operating-Cash-Flow | 10.34 | |||||
EV-to-EBIT | 10.44 | |||||
EV-to-Forward-EBIT | 9.78 | |||||
EV-to-EBITDA | 10.44 | |||||
EV-to-Forward-EBITDA | 8.4 | |||||
EV-to-Revenue | 2.71 | |||||
EV-to-Forward-Revenue | 2.14 | |||||
EV-to-FCF | 12.42 | |||||
Price-to-GF-Value | 1.18 | |||||
Price-to-Projected-FCF | 1.38 | |||||
Price-to-Median-PS-Value | 0.88 | |||||
Price-to-Graham-Number | 1.94 | |||||
Earnings Yield (Greenblatt) % | 9.58 | |||||
FCF Yield % | 8.01 | |||||
Forward Rate of Return (Yacktman) % | -2.22 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:SBHMY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sino Biopharmaceutical Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 4,894.285 | ||
| EPS (TTM) ($) | 0.397 | ||
| Beta | 0.398 | ||
| 3-Year Sharpe Ratio | 0.36 | ||
| 3-Year Sortino Ratio | 1.06 | ||
| Volatility % | 20.07 | ||
| 14-Day RSI | 65.18 | ||
| 14-Day ATR ($) | 0.021355 | ||
| 20-Day SMA ($) | 12.98375 | ||
| 12-1 Month Momentum % | -34.97 | ||
| 52-Week Range ($) | 11.27 - 20.16 | ||
| Shares Outstanding (Mil) | 890.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sino Biopharmaceutical Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sino Biopharmaceutical Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| USD 0.178539 Cash Dividend | 2026-09-02 | In 6 days | ||
| Second quarter earnings results for 2026 | 2026-08-19 | 13.01 (+0.00%) | ||
| USD 0.127537 Cash Dividend | 2026-06-25 | 12.68 (+0.00%) | ||
| General meeting for 2025 | 2026-06-17 11:00 | 11.27 (+0.00%) | ||
| Annual report for 2025 | 2026-04-29 | 14.29 (+0.00%) | ||
| USD 0.128597 Cash Dividend | 2025-08-29 | 20.16 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-18 | 19.50 (+0.00%) | ||
| USD 0.101909 Cash Dividend | 2025-06-17 | 9.48 (+0.00%) | ||
| General meeting for 2024 | 2025-06-10 15:00 | 9.48 (+0.00%) | ||
| Annual report for 2024 | 2025-04-29 | 9.48 (+0.00%) |
Show
Entries
Sino Biopharmaceutical Ltd Frequently Asked Questions
What is Sino Biopharmaceutical Ltd(SBHMY)'s stock price today?
The current price of SBHMY is $13.01. The 52 week high of SBHMY is $20.16 and 52 week low is $11.27.
When is next earnings date of Sino Biopharmaceutical Ltd(SBHMY)?
The next earnings date of Sino Biopharmaceutical Ltd(SBHMY) is 2027-02-19 Est..
Does Sino Biopharmaceutical Ltd(SBHMY) pay dividends? If so, how much?
The Dividend Yield %  of Sino Biopharmaceutical Ltd(SBHMY) is 1.97% (As of Today), Highest Dividend Payout Ratio of Sino Biopharmaceutical Ltd(SBHMY) was 0.75. The lowest was 0.05. And the median was 0.27. The  Forward Dividend Yield % of Sino Biopharmaceutical Ltd(SBHMY) is 2.35%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Sino Biopharmaceutical Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers